News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Potential $95 Million Ultragenyx Pharmaceuticals IPO Leads Biotech Class Of '14


1/30/2014 7:55:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rare disease drug developer Ultragenyx Pharmaceutical Inc. is expected to hit the market next week — the first of a new wave of biotech initial public offerings — with an IPO that could raise nearly $95 million. The Novato company, founded by former BioMarin Pharmaceutical Inc. chief medical officer Emil Kakkis, last week priced 4.8 million shares in its IPO at $14 to $17 per share. Ultragenyx, which would trade on the NASDAQ exchange as "RARE," has four drugs in clinical trials.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES